Article

Blood Pressure Meds Help Hypertensive Patients With Kidney Cancer

Blood Pressure Meds Help Hypertensive Patients With Kidney Cancer

High blood pressure medications called angiotensin system inhibitors (ASIs) impact blood flow to a tumor, which could make them an ideal addition to cancer treatment. Researchers looked at data from several studies that included participants with metastatic kidney cancer who received ASIs within the first 30 days of a clinical trial. Those trials were testing a variety of anticancer drugs, including Avastin (bevacizumab), Sutent (sunitinib), Torisel (temsirolimus) and interferon alfa. (You can view the results here.)

Retrospective data showed participants who took blood pressure medication along with their anticancer drug had longer survival and delayed tumor progression. Participants who received an antiangiogenic drug, such as Avastin (a drug that blocks blood flow to a tumor), along with an ASI experienced even more significant results, with an improvement in survival time of nine months compared with participants not receiving an ASI. Study subjects receiving an ASI and an mTOR inhibitor or interferon alfa did not experience a significant improvement.

Researchers are not encouraging the use of ASIs in nonhypertensive patients with advanced kidney cancer, but patients who have high blood pressure and receive antiangiogenic cancer treatment should certainly consider ASIs.

Related Videos
CURE spoke with Dr. William C. Huang about what kind of team may be required to treat a patient with metastatic kidney cancer.
Image of man wearing baseball cap backwards.
Dr. Emre Yekedüz highlighted strategies that may improve patients' quality of life and mitigate treatment-related side effects in renal cell carcinoma.
Dr. Guru Sonpavde emphasized the importance of better understanding how genetic mutations influence the treatment of cancer care, particularly GU cancers.
Image of doctor with brown hair.
Image of man with black hair.
.Dr. Catherine Wu, chief of the Division of Stem Cell Transplantation and Cellular Therapies at Dana-Farber Cancer Institute, and institute member at the Broad Institute of MIT and Harvard, in Boston
Dr. Katy Beckermann discusses how a Fotivda and Opdivo combination for renal cell carcinoma compared with Fotivda alone based on patient feedback.
Dr. Catherine Wu is chief of the Division of Stem Cell Transplantation and Cellular Therapies at Dana-Farber Cancer Institute, and institute member at the Broad Institute of MIT and Harvard, in Boston, Massachusetts.
Dr. Alan Tan is the GU Oncology Lead at the Vanderbilt-Ingram Cancer Center in Nashville, Tennessee, as well as an associate professor in the Division of Hematology/Oncology at Vanderbilt University Medical Center and GU Executive Officer with the Alliance for Clinical Trials in Oncology.
Related Content